ASC Therapeutics Inc

ASC Therapeutics is a privately held biopharmaceutical company developing gene replacement therapies, in vivo gene editing, and allogeneic cell therapies for hematological, metabolic, and other rare diseases. Its lead programs include ASC-618, a second-generation gene therapy for severe hemophilia A, and ASC-930, an allogeneic cell therapy for graft-versus-host disease.